MedTrace Logo

Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)

NCT01098084 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2014-03-20

No results posted yet for this study

Summary

The aim of this study is to determine the therapeutic efficacy of Decitabine in patients with chronic myelomonocytic leukemia (CMML) diagnosis according to WHO criteria either untreated or previously treated with Hydrea or Etoposide (given orally), non intensive chemotherapy or intensive chemotherapy given more than 3 months before inclusion.

Conditions

  • Chronic Myelomonocytic Leukemia

Interventions

DRUG

Decitabine

20mg/m2/day, one hour intravenous infusion, every day during 5 days

Sponsors & Collaborators

  • Janssen-Cilag Ltd.

    collaborator INDUSTRY

  • Groupe Francophone des Myelodysplasies

    lead OTHER

Principal Investigators

  • Eric Solary, MD, PhD · Gustave Roussy, Cancer Campus, Grand Paris

  • Thorsten Braun, MD,PhD · Avicenne Hospital, 93 000 Bobigny

  • Ingrid Lafon, MD · CHU Le Bocage, Dijon

Study Design

Allocation
NA
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01098084 on ClinicalTrials.gov